Sunday, December 11, 2016 5:03:25 PM
Last but not least the dumbest ideas the company could do is issue $6.05 warrants with a stock price barely hanging over $1.00.
Those warrants would be about 80% below being in the money and would trade for almost nothing.
The mythical $36 million in the God-awful example would only happen 5 years from now if the stock price is comfortably above $6.05. In much less years than that, NNVC will be completely bankrupt if it doesn't raise money in a more sane manner than this senile idea.
Shorts and the mythical "cabal" won't do anything but laugh and new shorts will be attracted. Nobody is going to give a shit about $6.05 worthless warrants on a $1.20 stock. Good grief lol is this for real? If issuing worthless warrants really helped a stock everybody would be doing it.
Usually warrants are just issued as a "sweetener" to an investment bank who buys deeply discounted dilutive shares. It's called a "sweetener" because they are just a gamble, at best, with little short term value. And those are warrants priced with a more enticing level such as say $1.50 warrants on a $1.20 stock. $6.05 warrants on a $1.20 stock? ROFL!!!!!!
Those warrants would be about 80% below being in the money and would trade for almost nothing.
The mythical $36 million in the God-awful example would only happen 5 years from now if the stock price is comfortably above $6.05. In much less years than that, NNVC will be completely bankrupt if it doesn't raise money in a more sane manner than this senile idea.
Shorts and the mythical "cabal" won't do anything but laugh and new shorts will be attracted. Nobody is going to give a shit about $6.05 worthless warrants on a $1.20 stock. Good grief lol is this for real? If issuing worthless warrants really helped a stock everybody would be doing it.
Usually warrants are just issued as a "sweetener" to an investment bank who buys deeply discounted dilutive shares. It's called a "sweetener" because they are just a gamble, at best, with little short term value. And those are warrants priced with a more enticing level such as say $1.50 warrants on a $1.20 stock. $6.05 warrants on a $1.20 stock? ROFL!!!!!!
The SwingTrade Portfolio was up 36.2% in 2014, 83.5% in 2013, and 546.6% since inception.
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=110307454
Recent NNVC News
- In the Ebola Emergency, NV-387 is Ready to be Shipped to DRC, and It Compares Favorably as a Treatment for Ebola Versus Possible Options, Says NanoViricides • ACCESS Newswire • 05/26/2026 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/21/2026 10:01:46 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/20/2026 08:30:33 PM
- NanoViricides Announces Closing of ~$2 Million Registered Direct Offering • ACCESS Newswire • 05/19/2026 03:55:00 AM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 05/18/2026 12:45:22 PM
- Ebola Global Health Emergency Needs a Broad-Spectrum Drug - NV-387 is a Strong Potential Candidate, Says NanoViricides • ACCESS Newswire • 05/18/2026 12:30:00 PM
- NanoViricides Announces Pricing of ~$2 Million Registered Direct Offering • ACCESS Newswire • 05/15/2026 12:35:00 PM
- NanoViricides, Inc. Has Filed its Quarterly Report - NV-387 Advancing for Phase II • ACCESS Newswire • 05/15/2026 12:00:00 PM
- Recent Hantavirus On A Cruise Ship Highlights the Need for Broad-Spectrum Antiviral Drugs Such as NV-387, Says NanoViricides • ACCESS Newswire • 05/11/2026 12:30:00 PM
- NanoViricides, Inc. Announces Participation in the D. Boral Capital Global Conference • Newsfile • 05/06/2026 07:37:00 PM
- NV-387 for The Treatment of Measles is Granted Orphan Drug Designation by The US FDA • ACCESS Newswire • 05/04/2026 12:30:00 PM
- Deadly Measles Cases Accentuate the Need for a Treatment - NV-387 is Here to Help Patients and Control Spread, Says NanoViricides • ACCESS Newswire • 04/21/2026 12:30:00 PM
- Measles Rare Pediatric Disease Drug Designation Application Filed for NV-387, PRV Provides for Strong Business Case, Says NanoViricides • ACCESS Newswire • 04/07/2026 12:30:00 PM
- Phase II Clinical Trial of Monkeypox Treatment by NV-387 to Commence Soon, Announces NanoViricides • ACCESS Newswire • 04/01/2026 12:30:00 PM
- NanoViricides Presenting at NIBA's 152nd Investment Conference in Fort Lauderdale, FL March 12, 2026 - Announces Manufacture of Phase II Clinical Product NV-387 Oral Gummies is Complete • ACCESS Newswire • 03/11/2026 12:30:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/17/2026 09:30:47 PM
- MPox Orphan Drug Designation Application Filed for NV-387, Declares NanoViricides • ACCESS Newswire • 02/12/2026 01:30:00 PM
- Measles Orphan Drug Designation Application Filed for NV-387, Declares NanoViricides • ACCESS Newswire • 02/10/2026 01:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 12/30/2025 09:30:18 PM
- Form DEL AM - Delaying amendment • Edgar (US Regulatory) • 12/16/2025 09:30:05 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 12/15/2025 09:26:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/26/2025 09:30:33 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:32:10 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/12/2025 07:54:28 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/12/2025 04:29:54 PM
